Neurological Presentations and CNS Pathology of Rosai-Dorfman disease: A 28-Year Report and Review from Single Tertiary Referral Institute in Thailand

Main Article Content

Samasuk Thammachantha
Pongwat Polpong
Kullapat Veerasan
Nitat Kiathiranon
Yodkhwan Wattanasen
Pungjai Keandoungchun
Patcharapim Masaya-anon

Abstract

Rosai-Dorfman Disease (RDD) is a benign systemic histio-proliferative disorder with a variable clinical presentation, depending on the sites of the lesion. Intracranial RDD is a form of sporadic extranodal type of RDD and usually occurs without lymphadenopathy. Most intracranial lesions are attached to the dura mimic meningioma; therefore, pathology is necessary to diagnose this rare entity. Pathology of RDD is characterized by numerous large histiocytic cells engulf the intact lymphocytes (Emperipolesis). Immunohistochemical stains of histiocytic cells are positive for CD68, S-100 protein but negative for CD1a. Surgery is the first line of treatment and post-operative corticosteroids or chemotherapy may be recommended in some cases. This article describes and summarizes the four cases of intracranial RDD encountered by the Neurological Institute of Thailand from 1992 to 2019 and highlights the clinical presentations, pathology, plan of treatments and outcome of disease in each occurrence.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Thammachantha S, Polpong P, Veerasan K, Kiathiranon N, Wattanasen Y, Keandoungchun P, Masaya-anon P. Neurological Presentations and CNS Pathology of Rosai-Dorfman disease: A 28-Year Report and Review from Single Tertiary Referral Institute in Thailand. BKK Med J [Internet]. 2022 Sep. 30 [cited 2022 Dec. 4];18(2):113. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/257479
Section
Case Report

References

Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. Arch Pathol 1969;87:63-70.

Symss NP, ugati G, Vasudevan MC, et al. Intracranial Rosai Dorfman disease: report of three cases and literature review. Asian J Neurosurg 2010;11:19-30.

Aljohani HT, Robin S. A rare case of isolated intracranial Rosai–Dorfman disease mimicking optic nerve meningioma: A case report and literature review. Asian J Neurosurg 2018;13(3):845-7. doi: 10.4103/ajns.AJNS_322_16.

Jiang Y, Jiang S. Intracranial meningeal Rosai-Dorfman disease mimicking multiple meningiomas: 3 case reports and a literature review. World Neurosurg 2018:120;382-90. doi: 10.1016/j.wneu.2018.09.060.

Shuangshoti SS. Jr, Navalitloha Y, Sukpanichnant S, et al. Central nervous system involvement in Rosai-Dorfman disease: Report of a case with a review of the literature. Neuropathology. 1999;19(3):341-

doi: https://doi. org/10.1046/j.1440-1789.1999.00242.x 6. Bruce-Brand C, Schneider W, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol 2020;73(11):697–705. doi:10.1136/jclinpath-2020-206733.

Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127(22): 2672-81. doi: 10.1182/ blood-2016-01-690636.

Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer 2014;61(7):1329- 35. doi: 10.1002/pbc.25017.

Kala C, Agarwal A, Kala S. Extranodal manifestation of Rosai–Dorfman disease with bilateral ocular involvement. J Cytol 2011;28(3):131–3. doi: 10.4103/0970-9371.83473.

Shukla E, Nicholson A, Agrawa A, et al. Extra nodal Rosai–Dorfman disease (sinus histiocytosis with massive lymphadenopathy) presenting as asymmetric bilateral optic atrophy: An atypical ocular presentation. Head Neck Pathol 2016;10:414-7. doi: 10.1007/s12105-016-0719-4.

Andriko JA, Morrison A, Colegial CH, et al. Rosai-Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001;14(3):172-8. doi: 10.1038/modpathol.3880278.

Menon MP, Evbuomwan MO, Rosai J, et al. A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease? Histopathology 2014;64(3):455-9. doi: 10.1111/his.12274.

Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154–65. doi: 10.1158/2159-8290. CD-15-0913.

Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 2017;30(10):1367-1377. doi: 10.1038/ modpathol. 2017.55.

Jin H, Yu Z, Tian T, et al. Rosai-Dorfman disease in the central nervous system with two isolated lesions originated from a single clone: a case report. BMC Neurol. 2021;21(1):352. doi: 10.1186/s12883-021-02379-2. 1

Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol 2002;69(1):67–71. doi: 10.1002/ajh.10008.

Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-DorfmanDestombes disease. Blood 2018;131:2877–90. doi: 10.1182/ blood-2018-03-839753.

Dalia S, Sagatys E, Sokol L, et al. Rosai–Dorfman disease: tumor biology, clinical features, pathology, and treatment. C a n c e r C o n t r o l 2 0 1 4 ; 2 1 ( 4 ) ; 3 2 2 - 7 . d o i : 10.1177/107327481402100408.

Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer 2014;61(7):1329-35. doi: 10.1002/pbc.25017.

Haroche J, Abla O. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and ErdheimChester disease. Hematology Am Soc Hematol Educ Program 2015;2015:571-8. doi: 10.1182/asheducation-2015.1.571.

Alqanatish JT, Houghton K, Bond M, et al. Rituximab treatment in a child with Rosai-Dorfman disease and systemic lupus erythematosus. J Rheumatol 2010;37:1783-4. doi: 10.3899/jrheum.091275.

Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol 2007;143:736-40. doi: 10.1001/archderm.143.6.736.

Safi SS, Murshed K, Ali A, et al. Rosai-Dorfman disease of cranial and spinal origin - A case series. Surg Neurol Int 2020;11:298. doi: 10.25259/SNI_391_2020.

Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019;567(7749):521-4. doi: 10.1038/s41586-019-1012-y.

Phusanti S, Kanoksil W, Tankunakorn J, et al. Disseminated Rosai-Dorfman disease with multiple extranodal involvement: a rare case report. J Hematol Transfus Med 2018;28:179-86.

Goyal G, Ravindran A, Young Jr, et al. Clinicopathological features, treatment approaches, and outcomes in RosaiDorfman disease. Haematologica 2020;105(2):348-57. doi: 10.3324/haematol.2019.219626.